Antenatal Magnesium Sulphate in High-Risk Preterm Patients
Recruiting
Phase 3
Interventional Study
Cerebral Palsy
Magnesium Sulfate Overdose
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 45
- Sex
- Female
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 138 (estimated)
- Sponsor
- Cairo University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to evaluate whether antenatal magnesium sulphate reduces the risk of cerebral palsy in infants born to women at high risk of preterm birth. It will also assess the safety of magnesium sulfate for both the mother and the neonate. The main question it aims to answer is whether magnesium sulphate given before anticipated preterm delivery decreases the incidence of c…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
* Inclusion Criteria:
* Pregnant women at high risk of preterm birth between 32 and 35 weeks of gestation
* Birth is planned or expected within 24 hours
* Singleton pregnancy
* No contraindication to antenatal magnesium sulphate
* Able to provide informed consent
* Exclusion Criteria:
…
Contacts